Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 4/2004

01-04-2004 | Article

Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare Homes

Authors: I. Tinoco, J. A. Girón-González, M. T. González-González, A. Vergara de Campos, L. Rodríguez-Félix, A. Serrano, A. Bascuñana

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 4/2004

Login to get access

Abstract

With the objective of analyzing the efficacy of directly observed treatment (DOT) of HIV infection in the management of severely immunodepressed patients, this method was examined in individuals cared for in two social welfare facilities for HIV-infected persons and compared to self-administered therapy in outpatients. Forty-seven patients with registered HIV infection, stage C, were assigned to DOT for 9 months, the majority of whom had previously received antiretroviral therapy. A group of 51 HIV-infected outpatients, who attended day clinics attached to the reference hospitals, served as a comparison group. Together with increases in weight (9.2±7.5 kg) and Karnofsky scores (16.9±12.2) in the DOT group, a significant improvement of surrogate markers, such as CD4+ T-cell counts (increase in DOT group, 113.4±151.0 cells/µl; control group, −2.8±114.1 cells/µl; P<0.001) and HIV load (decrease in DOT group, −1.7±2.3 log10 copies/ml; control group, −0.4±1.5 log10 copies/ml; P<0.01) was detected in the DOT group. Morbidity and mortality were similar in both groups. The results indicate that such welfare facilities provide a useful framework not only for social objectives but also for healthcare purposes.
Literature
1.
go back to reference Stone VE (2001) Strategies for optimizing adherence to highly active anti-retroviral therapy: lessons from research and clinical practice. Clin Infect Dis 33:865–872CrossRefPubMed Stone VE (2001) Strategies for optimizing adherence to highly active anti-retroviral therapy: lessons from research and clinical practice. Clin Infect Dis 33:865–872CrossRefPubMed
2.
go back to reference Woodward WC (1996) Should directly observed therapy be considered for treatment of HIV? JAMA 276:1956CrossRefPubMed Woodward WC (1996) Should directly observed therapy be considered for treatment of HIV? JAMA 276:1956CrossRefPubMed
3.
4.
go back to reference Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M (1998) Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 10:297–312PubMed Sorensen JL, Mascovich A, Wall TL, DePhilippis D, Batki SL, Chesney M (1998) Medication adherence strategies for drug abusers with HIV/AIDS. AIDS Care 10:297–312PubMed
5.
go back to reference Mitty JA, Mckenzie M, Stenzel M, Flanigan T, Carpenter CCJ (1999) Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 282:1334CrossRefPubMed Mitty JA, Mckenzie M, Stenzel M, Flanigan T, Carpenter CCJ (1999) Modified directly observed therapy for treatment of human immunodeficiency virus. JAMA 282:1334CrossRefPubMed
6.
go back to reference Chaulk CP, Kazandijian VA (1998) Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 279:943–948CrossRefPubMed Chaulk CP, Kazandijian VA (1998) Directly observed therapy for treatment completion of pulmonary tuberculosis. JAMA 279:943–948CrossRefPubMed
7.
go back to reference Babudiere S, Aceti A, D’Offizi GP, Carbonara S, Starnini G (2000) Directly observed therapy to treat HIV infection in prisoners. JAMA 284:179–180PubMed Babudiere S, Aceti A, D’Offizi GP, Carbonara S, Starnini G (2000) Directly observed therapy to treat HIV infection in prisoners. JAMA 284:179–180PubMed
8.
go back to reference Lanzafame M, Trevenzoli M, Cattelan AM, Lazzarini L, Vento Ercole Concia S (2000) Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 25:200–201CrossRefPubMed Lanzafame M, Trevenzoli M, Cattelan AM, Lazzarini L, Vento Ercole Concia S (2000) Directly observed therapy in HIV therapy: a realistic perspective? J Acquir Immune Defic Syndr 25:200–201CrossRefPubMed
9.
go back to reference Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T (2002) Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 34:984–990CrossRefPubMed Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T (2002) Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 34:984–990CrossRefPubMed
10.
go back to reference Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY (2001) Community-based approaches to HIV treatment in resource-poor setting. Lancet 358:404–409CrossRefPubMed Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC, Koenig SP, Castro A, Becerra MC, Sachs J, Attaran A, Kim JY (2001) Community-based approaches to HIV treatment in resource-poor setting. Lancet 358:404–409CrossRefPubMed
11.
go back to reference Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78–86CrossRefPubMed Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998) Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78–86CrossRefPubMed
12.
go back to reference Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:2936–2937 Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 283:2936–2937
13.
go back to reference McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–855 McCabe WR, Jackson GG (1962) Gram-negative bacteremia. I. Etiology and ecology. Arch Intern Med 110:847–855
14.
go back to reference Centers for Diseases Control (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:RR-17 Centers for Diseases Control (1992) 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41:RR-17
15.
go back to reference Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A, GEEMA Study Group (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 16:605–613CrossRefPubMed Knobel H, Alonso J, Casado JL, Collazos J, Gonzalez J, Ruiz I, Kindelan JM, Carmona A, Juega J, Ocampo A, GEEMA Study Group (2002) Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 16:605–613CrossRefPubMed
16.
go back to reference López-Suárez A, Fernández-Gutiérrez del Álamo C, Pérez-Guzmán E, Girón-González JA (1998) Adherence to antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 12:685–686PubMed López-Suárez A, Fernández-Gutiérrez del Álamo C, Pérez-Guzmán E, Girón-González JA (1998) Adherence to antiretroviral treatment in asymptomatic HIV-infected patients. AIDS 12:685–686PubMed
17.
go back to reference Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35–43CrossRef Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM (1999) HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 13:F35–43CrossRef
18.
go back to reference Torre D, Tambini R (2002) Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 3:1–8PubMed Torre D, Tambini R (2002) Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials 3:1–8PubMed
19.
go back to reference Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study. JAMA 282:2220–2226CrossRefPubMed Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A (1999) AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV Cohort Study. JAMA 282:2220–2226CrossRefPubMed
Metadata
Title
Efficacy of Directly Observed Treatment of HIV Infection: Experience in AIDS Welfare Homes
Authors
I. Tinoco
J. A. Girón-González
M. T. González-González
A. Vergara de Campos
L. Rodríguez-Félix
A. Serrano
A. Bascuñana
Publication date
01-04-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 4/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1099-8

Other articles of this Issue 4/2004

European Journal of Clinical Microbiology & Infectious Diseases 4/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.